

1 **Bacterial culture use, etiology and antibiotic susceptibility of common bacterial**  
2 **infections in Indonesian hospitals in 2019**

3 **Authors**

4 Justin de Brabander<sup>1,2</sup>, Erni J. Nelwan<sup>3,4,5,6</sup>, Ralalicia Limato<sup>1,7</sup>, Monik Alamanda<sup>1</sup>, Manzilina  
5 Mudia<sup>1</sup>, Enty Tjoa<sup>8,9</sup>, Ifael Y. Mauleti<sup>10</sup>, Maria Mayasari<sup>11</sup>, Iman Firmansyah<sup>12</sup>, T. Mannaria  
6 Jayati<sup>6</sup>, Michèle van Vugt<sup>2</sup>, H. Rogier van Doorn<sup>7,13</sup>, Raph L. Hamers<sup>1,3,7</sup>

7 **Affiliations**

- 8 1. Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia
- 9 2. Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC,  
10 University of Amsterdam, Amsterdam, The Netherlands
- 11 3. Faculty of Medicine, University of Indonesia, Jakarta, Indonesia
- 12 4. Department of Internal Medicine, Division of Infectious Diseases, Cipto Mangunkusumo  
13 National General Hospital, Jakarta, Indonesia
- 14 5. Infectious Disease and Immunology Research Cluster, Indonesian Medical Education and  
15 Research Institute, Jakarta, Indonesia
- 16 6. Metropolitan Medical Centre Hospital, Jakarta, Indonesia
- 17 7. Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University  
18 of Oxford, Oxford, UK
- 19 8. Royal Taruma Hospital, Jakarta, Indonesia
- 20 9. School of Medicine and Health Sciences, Atma Jaya Catholic University, Jakarta, Indonesia
- 21 10. Fatmawati General Hospital, Jakarta, Indonesia
- 22 11. St. Carolus Hospital, Jakarta, Indonesia
- 23 12. Prof. Dr. Sulianti Saroso Infectious Disease Hospital, Jakarta, Indonesia
- 24 13. Oxford University Clinical Research Unit, Hanoi, Vietnam

25

26 **\*Corresponding author**

27 Raph L. Hamers MD PhD

28 Email : raph.hamers@ndm.ox.ac.uk

29 Phone : +62 21 31900971

30 Fax : -

31

32 **Running title:** Antibiotic resistance in Indonesian hospitals

33 **Word count:** 1499

34 **Inserts:** 2 figures

35 **Supplementary data:** 4 tables; 3 figures

36 **Abstract**

37

38 **Objectives:** To describe the use of bacterial cultures, and the etiology and antibiotic  
39 susceptibility of common high-priority bacteria isolated from hospitalized patients in Jakarta,  
40 Indonesia.

41 **Methods:** We conducted a hospital-wide cross-sectional study of all inpatients receiving  
42 systemic antibiotic treatment (WHO ATC J01) in six hospitals in 2019, capturing routine data on  
43 antibiotic treatment and cultures. We reported bug-drug combinations for *Escherichia coli* and  
44 the ESKAPE group of bacteria.

45 **Results:** 562 patients (52% women, median age 46 years) had 587 diagnoses, with pneumonia  
46 (258, 44%) most common. One or more culture specimens were taken in 38% (215/562) overall,  
47 a sputum culture in 25% (64/258) of pneumonia patients; and a blood culture in 52% (16/31) of  
48 sepsis patients. 50% of positive blood culture results were reported after  $\geq 4$  days. From 670  
49 culture specimens, 279 bacteria were isolated, 214 (77%) were Gram-negative, including  
50 *Klebsiella pneumoniae* (70, 25%), *Pseudomonas aeruginosa* (36, 13%), and *E. coli* (21, 11%).  
51 Resistance included third-generation cephalosporin-resistant *K. pneumoniae* (77%), *E. coli*  
52 (65%) and *Enterobacter spp* (81%); carbapenem-resistant *K. pneumoniae* (26%), *P. aeruginosa*  
53 (24%), *E. coli* (33%), *Acinetobacter spp* (57%), and *Enterobacter spp* (60%); and meticillin-  
54 resistant *S. aureus* (71%). Vancomycin-resistant *S. aureus* (0%) and *Enterococcus faecalis*  
55 (12%) were uncommon. Multi-drug resistance was 30% for *K. pneumoniae*, 29% for *P.*  
56 *aeruginosa*, 49% for *E. coli*, 42% for *Acinetobacter spp*, and 71% for *S. aureus*.

57 **Conclusions:** In Indonesian hospitals, bacterial cultures were underused and antibiotic  
58 resistance is at alarming levels. Enhanced context-specific infection prevention, diagnostic and  
59 antibiotic stewardship interventions are urgently needed.

## 60 **Introduction**

61  
62 Antibiotic-resistant bacterial infections caused an estimated 1.27 million deaths in 2019, with  
63 worst impacts in low- and middle-income countries (LMICs).<sup>1</sup> The consumption of antimicrobial  
64 agents is one of the key drivers of antimicrobial resistance (AMR).<sup>2,3</sup> Continuous epidemiological  
65 surveillance of AMR patterns in each country and hospital is warranted to establish evidence-  
66 based policies. Southeast Asia has been identified of great importance in the emergence and  
67 spread of AMR.<sup>4,5</sup> Indonesia, a diverse lower-middle-income country with the world's fourth  
68 largest populace (275 million), is particularly vulnerable to AMR<sup>6</sup>, because of rapidly increasing  
69 antibiotic consumption<sup>7</sup> and weakly enforced antibiotic policies.<sup>8</sup> Systemic data are lacking to  
70 estimate the extent of AMR in hospitals.<sup>9-11</sup>

71  
72 This study aimed to describe the use of bacterial cultures, and the etiology and antibiotic  
73 susceptibility of common high-priority bacterial infections in hospitalized patients in Jakarta,  
74 Indonesia.

## 75 76 **Materials and methods**

### 77 78 Study design and setting

79 We conducted a hospital-wide cross-sectional survey in a purposively varied sample of six  
80 hospitals (3 private and 3 public; 4 secondary and 2 tertiary) in Jakarta between March and  
81 August 2019, as previously described.<sup>12</sup> The present analysis included all inpatients who started  
82 systemic antibiotic treatment (ATC J01) for a presumed bacterial infection, and we extracted  
83 data from medical and laboratory records. Antibiotic indications were classified as community  
84 acquired infection (CAI) (symptoms present on admission or started <48 hours after admission),  
85 or hospital acquired infection (HAI) (symptoms started >48 hours after admission at the study

86 site). The study was approved by the Research Ethics Committee of the Faculty of Medicine of  
87 the University of Indonesia and the Oxford Tropical Research Ethics Committee; the  
88 requirement for individual patient consent was waived.

89

#### 90 Microbiological diagnostic testing

91 All culture specimens taken as part of routine clinical care during their current admission  
92 (including <7 days prior) were included. Non-susceptibility was defined as intermediate or  
93 resistant, based on CSLI and/or EUCAST breakpoints. The analysis focused on the most  
94 relevant bacteria for hospital settings, *Enterococcus* species, *Staphylococcus aureus*, *Klebsiella*  
95 *pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa* and *Enterobacter* species,  
96 (i.e. ESKAPE group), and *Escherichia coli*, and common bacteria-antibiotic combinations  
97 (including those in the WHO priority pathogen list<sup>13</sup>). Multi-drug resistance was defined as non-  
98 susceptibility to at least one agent in three or more antimicrobial categories, based on the 2011  
99 ECDC definition.<sup>14</sup> Where susceptibility results were given for more than one antibiotic of a  
100 same class (e.g. fluoroquinolones, carbapenems), the highest resistance proportion was  
101 selected to represent the proportion for that respective class.

102

#### 103 Statistical analysis

104 Data are presented as counts (percentage of total), mean ( $\pm$ SD) or median [IQR]. Differences  
105 between subgroups were analyzed using the Pearson's chi-squared test, unpaired t-test or  
106 Mann-Whitney U test, whichever appropriate. P-values of <0.05 were considered statistically  
107 significant. All statistical analyses were performed using R version 4.1.0.

108

## 109 **Results**

110

#### 111 Patient characteristics

112 Among 1602 hospitalized patients, 562 (35.1%) received one or more antibiotics for the  
113 treatment of a presumed bacterial infection (**Figure S1**). This comprised 777 prescriptions for  
114 587 distinct diagnoses, the most common being pneumonia (44.0%, 258), followed by skin and  
115 soft tissue (SST) (12.6%, 74), gastrointestinal (10.9%, 64), urinary tract (UTI) (7.7%, 45) and  
116 intra-abdominal infections (5.5%, 32), and sepsis (5.3%, 31). This included 69.8% (542) CAIs  
117 and 30.2% (235) HAIs. The median age was 46 years (IQR 20-60), and 52% were women.  
118 33.8% (190) of patients had been hospitalized in the three months before their current  
119 admission, and 23.8% (134) had undergone surgery in the previous three months. On average,  
120 patients who had one or more bacterial cultures taken, compared to those who had not, were  
121 younger, had lower body weight, and were more likely to have national health insurance, one or  
122 more catheters and a history of recent surgery or hospitalization (**Table S1**).

123

#### 124 Use and reporting of bacterial cultures

125 Proportions of patients in whom one or more bacterial cultures were performed were 38.3%  
126 (215/562) overall; 39.9% (103/258) of pneumonia patients (sputum 24.8% [64] and blood 20.5%  
127 [53]); 44.6% (33/74) of skin and soft tissue (SST) infection patients (wound 25.7% [19], blood  
128 14.9% [11], pus 13.5% [10]); 51.1% of urinary tract infection (UTI) patients (urine 44.4% [20]  
129 and blood 33.3% [15]); and 54.8% (17/31) of sepsis patients (blood 51.6% [16]) (**Figure S2**).

130 The median time from culture specimen collection to reporting positive results (etiology and  
131 antibiotic-susceptibility) was 4 (3-4) days for blood, 3 (2-4) days for sputum and 3 (2-3) days for  
132 urine (**Figure S3**).

133

#### 134 Bacterial etiology of infectious syndromes

135 Overall, 279 bacteria were isolated from 670 culture specimens, including 100 bacterial isolates  
136 from 239 culture specimens in CAI and 179 isolates from 431 culture specimens in HAI (**Figure**  
137 **1**). The proportion of positive blood cultures was 14.8% (39/263). Overall, 76.7% (214/279) of

138 isolates were Gram-negative bacteria. Most common bacteria were *K. pneumoniae* (25.1%, 70),  
139 *P. aeruginosa* (12.9%, 36), *E. coli*, coagulase-negative staphylococci (each 11.8%, 33),  
140 *Acinetobacter spp* (10.8%, 30) and *Enterobacter spp* (9.0%, 25) (**Table S2**). *Enterococcus*  
141 *faecium* was not isolated.

142  
143 **Table S2** summarizes etiologies of CAIs and HAIs. In both community-acquired and hospital-  
144 acquired pneumonia, the most frequent isolates were *K. pneumoniae* (26.5% [9/34] and 36.8%  
145 [25/68], respectively), *Acinetobacter spp* (26.5% [9/34] and 19.1% [13/68], respectively) and *P.*  
146 *aeruginosa* (20.6% [7/34] and 17.6% [12/68], respectively).

147

#### 148 Antibiotic susceptibility

149 Among *K. pneumoniae* isolates, non-susceptibility proportions were 77% (64/83) for third-  
150 generation cephalosporins (3GC), 26% (12/47) for carbapenems, 60% (50/84) for  
151 fluoroquinolones, and 50% (11/22) for cotrimoxazole (**Figure 2, Table S3-4**). Among *P.*  
152 *aeruginosa* isolates, non-susceptibility proportions were 24% (4/17) for carbapenems, 33%  
153 (14/43) for fluoroquinolones, 27% (13/48) for amikacin and 42% (20/48) for gentamicin. Among  
154 *E. coli* isolates, non-susceptibility proportions were 33% (4/12) for carbapenems, 57% (16/28)  
155 for fluoroquinolones, 65% (26/40) for 3GC, 51% (20/39) for gentamicin, 13% (5/39) for amikacin  
156 and 77% (10/13) for cotrimoxazole. Among *Acinetobacter spp* isolates, non-susceptibility  
157 proportions was 57% (8/14) for carbapenems. Among *Enterobacter spp* isolates, non-  
158 susceptibility proportions were 81% (21/26) for ceftazidime, 60% (3/5) for carbapenems, 44%  
159 (8/18) for fluoroquinolones, 43% (12/28) for amikacin, 57% (16/28) for gentamicin and 13% (1/8)  
160 for cotrimoxazole. Among *S. aureus* isolates, non-susceptibility proportions were 71% (5/7) for  
161 oxacillin and 0% (0/11) for vancomycin. Among *E. faecalis* isolates, non-susceptibility  
162 proportions was 12% (2/17) for vancomycin and 60% (9/15) for ampicillin.

163

164 Multi-drug resistance was 30% (26/86) for *K. pneumoniae*, 29% (14/49) for *P. aeruginosa*, 49%  
165 (20/41) for *E. coli*, 42% (15/36) for *Acinetobacter spp*, and 71% (5/7) for *S. aureus*.

166

## 167 **Discussion**

168

169 This “snapshot” study in Indonesian hospitals in 2019 suggested that AMR levels may be  
170 among the highest reported in national AMR surveillance reports from Southeast Asia, and  
171 substantially higher than those reported from Europe.<sup>15</sup> Resistance proportions were at alarming  
172 levels for the WHO-defined high-priority bacteria-antibiotic combinations,<sup>13</sup> i.e. 3GC-resistant *K.*  
173 *pneumoniae* (77%) and *E. coli* (65%); carbapenem-resistant *K. pneumoniae* (26%), *P.*  
174 *aeruginosa* (24%), *E. coli* (33%), *Acinetobacter spp* (57%), *Enterobacter spp* (60%); and  
175 meticillin-resistant *S. aureus* (71%). Our findings are in line with the first Indonesian submission  
176 from 20 tertiary sentinel hospitals to the pathogen-focused WHO Global Antimicrobial  
177 Resistance and Use Surveillance System (GLASS) in 2020,<sup>15</sup> which reported 79% 3GC-  
178 resistant *K. pneumoniae*, 40% meticillin-resistant *S. aureus*, 4% carbapenem-resistant *E. coli*,  
179 65% fluoroquinolone-resistant *E. coli* and 51% carbapenem-resistant *Acinetobacter spp* in blood  
180 specimens. For reference, between 2016-2020, *K. pneumoniae* resistance to 3GC and  
181 carbapenems was 32% and 5% in Malaysia, 53% and 27% in Vietnam, 54% and 21% in  
182 Philippines and 31% and 8% in Europe respectively.<sup>16</sup> *P. aeruginosa* resistance to  
183 fluoroquinolones and carbapenems were 6% and 8% in Malaysia, 43% and 45% in Vietnam,  
184 13% and 17% in Philippines and 19% and 17% in Europe respectively.<sup>17,18</sup> *S. aureus* resistance  
185 to meticillin was 18% in Malaysia, 51% in Philippines and 16% in Europe.

186

187 The study also demonstrated that the potential of bacterial cultures to target antibiotic therapy  
188 was substantially underused. Notably, a blood culture was taken in just over half of the sepsis  
189 patients, and a sputum culture in a quarter of pneumonia patients. Moreover, positive blood



190 culture results often reached the treating clinicians with delays, limiting clinical decision-making  
191 on de-escalating or stopping antibiotics. Culture underuse may be due to lack of laboratory  
192 capacity, cost-prohibitive bacterial culture testing and thresholds of national health insurance  
193 coverage, absence of clear culture guidelines, as well as long turnaround time and/or lack of  
194 trust in the results.<sup>19</sup>

195  
196 The study has some limitations. First, the reliance on routinely collected culture specimens may  
197 have caused overrepresentation of drug-resistant infections, given that a culture may have been  
198 preferentially performed on more severe, non-responding and antibiotic-treated patients.<sup>19</sup>

199 Second, the use of routine data may have caused variations in, for instance, clinical diagnosis,  
200 antibiotic indications, and quality and interpretation of culture results. Lastly, the limited hospital  
201 sample precludes generalizing the findings to other hospitals or the country. More granular AMR  
202 data are required to better estimate the extent of the problem, at the national and hospital  
203 levels, across the spectrum from tertiary to peripheral facilities.

204  
205 In conclusion, despite progress in implementing Indonesia's National Action Plan on AMR, there  
206 is a great need for stronger, more granular AMR surveillance, coupled with inter-disciplinary  
207 implementation research on stewardship interventions to inform local antibiotic guidelines and  
208 stewardship programs.

209 **Acknowledgements**

210 The authors are grateful to the management, research/medical committees and clinical staff of  
211 the participating hospitals for their support to the study.

212

213 **EXPLAIN study group**

214 Erni J. Nelwan, Ralalicia Limato, Manzilina Mudia, Monik Alamanda, Helio Guterres, Enty Enty,  
215 Ifael Y. Mauleti, Maria Mayasari, Iman Firmansyah, May Hizrani, Anis Karuniawati, Prof Taralan  
216 Tambunan, Prof Amin Soebandrio, Decy Subekti, Iqbal Elyazar, Mutia Rahardjani, Fitria  
217 Wulandari, Prof Reinout van Crevel, H. Rogier van Doorn, Vu Thi Lan Huong, Nga Do Ti Thuy,  
218 Sonia Lewycka, Prof Alex Broom, Raph L. Hamers.

219

220 **Funding**

221 This work and RLH And HRVD are supported by the Wellcome Africa Asia Programme Vietnam  
222 (106680/Z/14/Z). RL is supported by an OUCRU Prize Studentship and a Nuffield Dept of  
223 Medicine Tropical Network Fund DPhil Bursary.

224

225 **Transparency declarations**

226 None to declare

227

228 **Author contributions**

229 EJM and RLH conceived the idea for the study and are the principal investigators. RLH and RL  
230 obtained the funding. RL, EJM, HVTL and RLH designed the study protocol and developed the  
231 study instrument. MM, ERM, IYM, MM, IF, and RD collected and verified the data, overseen by  
232 RL. RL, MM, MA, JDB created and curated the database. JDB performed the analysis and had  
233 full access to all study data. JDB drafted the paper, with critical inputs from RLH. All authors  
234 critically revised the manuscript and gave approval for the final version to be published.

235

236 **Data Availability Statement**

237 De-identified data are available upon reasonable request via the corresponding author, after


238 written permission has been obtained from the lead investigators.

239 **References**

- 240 1. Antimicrobial Resistance C. Global burden of bacterial antimicrobial resistance in 2019:  
241 a systematic analysis. *Lancet* 2022.
- 242 2. Van Boeckel TP, Gandra S, Ashok A et al. Global antibiotic consumption 2000 to 2010:  
243 an analysis of national pharmaceutical sales data. *Lancet Infect Dis* 2014; **14**: 742-50.
- 244 3. Klein EY, Van Boeckel TP, Martinez EM et al. Global increase and geographic  
245 convergence in antibiotic consumption between 2000 and 2015. *Proc Natl Acad Sci U S A* 2018;  
246 **115**: E3463-E70.
- 247 4. Gandra S, Alvarez-Uria G, Turner P et al. Antimicrobial Resistance Surveillance in Low-  
248 and Middle-Income Countries: Progress and Challenges in Eight South Asian and Southeast  
249 Asian Countries. *Clin Microbiol Rev* 2020; **33**.
- 250 5. Chereau F, Opatowski L, Tourdjman M et al. Risk assessment for antibiotic resistance in  
251 South East Asia. *BMJ* 2017; **358**: j3393.
- 252 6. Menteri Kesehatan Republik Indonesia. Program Pengendalian Resistensi Antimikroba  
253 Di Rumah Sakit. 2015.
- 254 7. The Center for Disease DEP. ResistanceMap: Antibiotic resistance.  
255 <https://resistancemap.cddep.org/AntibioticUse.php> (September 28, 2021).
- 256 8. Zellweger RM, Carrique-Mas J, Limmathurotsakul D et al. A current perspective on  
257 antimicrobial resistance in Southeast Asia. *J Antimicrob Chemother* 2017; **72**: 2963-72.
- 258 9. Parathon H, Kuntaman K, Widiastoety TH et al. Progress towards antimicrobial  
259 resistance containment and control in Indonesia. *BMJ* 2017; **358**: j3808.
- 260 10. Lestari ES, Severin JA, Filius PM et al. Antimicrobial resistance among commensal  
261 isolates of *Escherichia coli* and *Staphylococcus aureus* in the Indonesian population inside and  
262 outside hospitals. *Eur J Clin Microbiol Infect Dis* 2008; **27**: 45-51.


- 263 11. Mendes RE, Mendoza M, Banga Singh KK et al. Regional resistance surveillance  
264 program results for 12 Asia-Pacific nations (2011). *Antimicrob Agents Chemother* 2013; **57**:  
265 5721-6.
- 266 12. Limato R, Nelwan EJ, Mudia M et al. A multicentre point prevalence survey of patterns  
267 and quality of antibiotic prescribing in Indonesian hospitals. *JAC Antimicrob Resist* 2021; **3**:  
268 dlab047.
- 269 13. Tacconelli E, Carrara E, Savoldi A et al. Discovery, research, and development of new  
270 antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. *Lancet Infect*  
271 *Dis* 2018; **18**: 318-27.
- 272 14. Magiorakos AP, Srinivasan A, Carey RB et al. Multidrug-resistant, extensively drug-  
273 resistant and pandrug-resistant bacteria: an international expert proposal for interim standard  
274 definitions for acquired resistance. *Clin Microbiol Infect* 2012; **18**: 268-81.
- 275 15. World Health Organization. Global antimicrobial resistance and use surveillance systems  
276 | Country Profiles. [https://www.who.int/data/gho/data/themes/topics/global-antimicrobial-](https://www.who.int/data/gho/data/themes/topics/global-antimicrobial-resistance-surveillance-system-glass/glass-country-profiles)  
277 [resistance-surveillance-system-glass/glass-country-profiles](https://www.who.int/data/gho/data/themes/topics/global-antimicrobial-resistance-surveillance-system-glass/glass-country-profiles) (October 19, 2021).
- 278 16. Vu TVD, Choisy M, Do TTN et al. Antimicrobial susceptibility testing results from 13  
279 hospitals in Viet Nam: VINARES 2016-2017. *Antimicrob Resist Infect Control* 2021; **10**: 78.
- 280 17. Antibiotic Resistance Surveillance Reference Laboratory KL, Malaysia,. National  
281 Antibiotic Resistance Surveillance Report 2019. 2019.
- 282 18. Manila: Antimicrobial Resistance Surveillance Program. Antimicrobial Resistance  
283 Surveillance Program Annual Report - 2020. 2021.
- 284 19. Lim C, Ashley EA, Hamers RL et al. Surveillance strategies using routine microbiology  
285 for antimicrobial resistance in low- and middle-income countries. *Clin Microbiol Infect* 2021; **27**:  
286 1391-9.

**Figure 1:** Etiology of community-acquired and hospital-acquired infections.



The category 'Other' comprised coagulase-negative staphylococci (12%, n=33), *Serratia marcescens* (2%, n=5), *Klebsiella oxytoca*, viridans group streptococci (each 1%, n=3), *Proteus mirabilis*, *Vibrio vulnificus*, *Moraxella catarrhalis* (each 1%, n=2), and *Stenotrophomonas maltophilia*, *Citrobacter freundii*, *Streptococcus mitis*, *Pseudomonas putida*, *Enterococcus avium*, *Morganella morganii* and *Proteus vulgaris* (each <1%).

**Figure 2:** Proportion of non-susceptibility among common Gram-negative and Gram-positive isolates.



Abbreviations: AMK = amikacin, AMP = ampicillin, CAZ = ceftazidime, CIP = ciprofloxacin, CLI = clindamycin, CRO = ceftriaxone, CTX = cefotaxime, DOR = doripenem, ERY = erythromycin, GEN = gentamicin, IPM = imipenem, LVX = levofloxacin, LZD = linezolid, MEM = meropenem, OXA = oxacillin, SXT = trimethoprim-sulphamethoxazole, TGP = tigecycline, TZP = piperacillin/tazobactam, VAN = vancomycin.